

What are the Most Cited Papers Published in *Value in Health*?

Michael Drummond, PhD, University of York, Heslington, York, UK, and **C. Daniel Mullins, PhD**, University of Maryland, Baltimore, MD, USA, *Value in Health* Co-Editors-in-Chief



In this article, we discuss the top 10 most cited papers published in *Value in Health* in 2014. These papers are just coming to the end of the first year of their two-year citation window and some patterns are beginning to emerge. Citations are an important indicator of the interest the papers are generating among the scientific community. Therefore, we here at *Value in Health* thought it would be useful to let *Value and Outcomes Spotlight* readers know which papers are generating the most interest.

The references of the 10 most cited papers are given in the table to the right. ISPOR Task Force reports are well represented in the list. The recently updated report on budget impact analysis by Sullivan et al. is the second-most cited paper, probably reflecting the wide use of these analyses in some countries. Three other papers on the list, including the most cited paper, are the products of a joint task force established by ISPOR, the Academy of Managed Care Pharmacy, and the National Pharmaceutical Council. The objective of this task force was to help decision makers assess the relevance and credibility of the pharmaco-economic and outcomes research studies that encounter. Therefore, each of the three papers presents a consensus-based questionnaire to help decision makers assess published papers or company submissions involving indirect comparisons/network meta-analyses (Jansen et al.), modeling studies (Caro et al.) and observational studies (Berger et al.).

The third most highly cited paper is by Berntgen et al., reporting on collaboration between the European Medicines Agency and the European Network for Health Technology Assessment (HTA) concerning how to improve the contribution of regulatory assessment reports to HTA. Although the paper focuses on the European context, the issue of getting better alignment between regulatory and HTA activities in their consideration and use of clinical data has worldwide relevance.

Another interesting policy issue is explored by Edlin et al. Their paper considers the challenge of implementing high-cost innovative technologies in health care systems operating under significant budgetary pressure. They propose a technology leasing reimbursement scheme that allows the sharing of risk between the manufacturer and the payer by replacing up-front payments with a stream of payments spread over the expected duration of benefit from the technology; subject to the technology delivering the claimed health benefit.

The final four papers on the list reflect the wide range of topics covered in papers published in *Value in Health*. These are by Thompson et al. on the cost-effectiveness of a pharmacogenetic test, by Collins et al. on an economic evaluation of salt reduction strategies to reduce coronary heart disease, by McEwan et al. on the validation of a model in diabetes and by Jönsson and et al. on the quantitative impact of different approaches for analyzing overall survival in randomized controlled trials that allow patients to crossover to the active treatment at disease progression, a common approach in studies of new cancer treatments. ■

TOP 10 MOST CITED PAPERS PUBLISHED IN *VALUE IN HEALTH* IN 2014

- 1 Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report**
Jansen, JP et al.
Vol. 17(2): 157-173
- 2 Budget Impact Analysis – Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force**
Sullivan, SD et al.
Vol. 17(1): 5-14
- 3 Improving the Contribution of Regulatory Assessment Reports to Health Technology Assessments – Collaboration between the European Medicines Agency and the European network for Health Technology Assessment**
Berntgen, M et al.
Vol. 17(5): 634-641
- 4 The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine**
Thompson, AJ et al.
Vol. 17(1): 22-33
- 5 Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report**
Caro, JJ et al.
Vol. 17(2): 174-182
- 6 A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report**
Berger, ML et al.
Vol. 17(2): 143-156
- 7 Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies?**
Edlin, R et al.
Vol. 17(4): 438-444
- 8 An Economic Evaluation of Salt Reduction Policies to Reduce Coronary Heart Disease in England: A Policy Modeling Study**
Collins, M et al.
Vol. 17(5): 517-524
- 9 Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation**
Jönsson, L et al.
Vol. 17(6): 707-713
- 10 Validation of the IMS CORE Diabetes Model**
McEwan, P et al.
Vol. 17(6): 714-724